# Is DexCom Inc (DXCM) overvalued?

Source: https://www.equity-rank.com/is-it-overvalued/DXCM

**On Equity Rank's model estimate, DXCM trades close to its fair value (1% above it).** DexCom Inc (DXCM) last closed at $79.41; the multi-method model fair value is $78.49.

| Price | Model fair value | Price vs model |
| --- | --- | --- |
| $79.41 | $78.49 | 1% above |

## What the answer rests on

- 1 of 9 valuation methods put DXCM's value above its price and 8 put it below, so the methods mostly agree.
- To justify today's price, DXCM's free cash flow would need to grow about 16.0% a year for ten years (a reverse discounted cash flow). Over the last three years it actually grew 52.3% a year.
- DXCM trades at 34.8 times its last year's earnings, against a median of 30.9 for 37 profitable Medical Devices companies.
- Over the past year the price sat below the model fair value on 7% of trading days. The gap ranged from 19% below to 30% above the model fair value.

## Read this before relying on it

The model fair value is an estimate from published financial statements. It is not a forecast of where the price goes, and it can be wrong. Within 10% either side we call it close to fair value: valuation models are not precise enough to read more into a smaller gap. Our own lists have no proven edge over the market yet; [the live record](https://www.equity-rank.com/track-record) shows every result, misses included.

Data as of Fri, Nov 6, 2026. Informational only — not investment advice.

[Every valuation method behind DXCM's fair value](https://www.equity-rank.com/stocks/DXCM) · [What prices assume](https://www.equity-rank.com/priced-in) · [Other companies](https://www.equity-rank.com/is-it-overvalued)

---

Fair value is a model estimate under stated assumptions — not a price target, not a prediction, and not a recommendation. This page is research information, not investment advice. Equity Rank is not a registered investment adviser.